A recent review in JAMA Network Open examined how social media influencers affect how people learn about and approach prescription medications, finding that influencer promotion of prescription drugs is often accompanied by misleading information and outdated regulatory oversight.
Study author Raffael Heiss, PhD, professor at Management Center Innsbruck, said influencers frequently share advice about prescription drugs despite financial incentives or little medical expertise. “Existing rules and disclosure requirements have not kept pace with social media,” Heiss said. The review also found that audiences may struggle to recognize promotional intent when marketing is embedded in personal narratives. “Personal stories can also make promotional content feel trustworthy and authentic, even when it is incomplete or misleading,” Heiss added.
Prescription drug companies increasingly partner with social media influencers, including “patient influencers” who post personal stories that make their messages persuasive. While such content can provide support and reduce isolation for some, the review warns it can also spread misinformation, encourage misuse, or lead to harmful interactions—especially when promotions come from healthcare professionals.
Kanwar Kelley, MD, who was not involved in the study, noted that influencer content can blur the line between clinical advice and trend following: “In today’s social media, that content is nearly indistinguishable from professional advice and can skirt the skepticism that people apply to traditional prescription marketing.” He emphasized that anecdotal evidence is not clinical evidence and called for clearer disclosure of conflicts of interest and mandatory discussion of risks, benefits, and alternatives.
The review analyzed 12 peer‑reviewed articles covering topics such as contraceptive advertising, performance‑enhancing drugs, and broader pharmaceutical promotion. All 12 articles identified recurring themes:
– Ineffective regulatory oversight and inconsistent disclosure practices
– Misinformation arising from influencers’ limited expertise amid audiences’ low health literacy
– Parasocial narratives that blur personal testimony and paid promotion
Researchers say the evidence base is small and fragmented but underscores an urgent need for updated regulatory guidance, enforceable and standardized disclosure requirements, targeted digital health literacy initiatives, and stronger platform accountability.
Nissa Keyashian, MD, a board‑certified psychiatrist not involved in the research, advises people to consider an influencer’s clinical education and any conflicts of interest or sponsorships, and whether these are disclosed clearly.
Heiss recommended caution when influencers promote prescription drugs, whether or not sponsorship is disclosed. People should be especially wary when influencers emphasize benefits, downplay risks, or embed drug recommendations in emotional personal stories. Before acting on online advice, discuss it with a doctor or pharmacist.
The review’s authors and outside experts agree that improving patient‑physician dialogue and refining digital advertising frameworks are key to protecting patient safety and trust as social media continues to shape how people get health information.
